RAMM Pharma Corp. Announces Corporate Update.
RAMM Pharma Corp. Announces Corporate Update.
TORONTO, Nov. 17, 2023 (GLOBE NEWSWIRE) -- On September 5th 2023, RAMM Pharma Corp. (including its wholly owned subsidiaries, the "Company" or "RAMM") (CSE: RAMM), announced its intention to complete a non-brokered private placement of up to 20,000,000 units (the "Units") of the Company at a price of $0.05 per Unit for total gross proceeds of up to $1,000,000 (the "Offering"). Each Unit would have been comprised of one common share in the capital of the Company (each, a "Common Share"), and one Common Share purchase warrant (each a "Warrant"), with each Warrant entitling the holder thereof to acquire one Common Share at a price of $0.05 for a period of 36 months following the closing date of the Offering. The proceeds from the Offering were expected to be used for working capital and general corporate purposes. The Offering was expected to close on or about September 26, 2023.
多倫多，2023年11月17日（GLOBE NEWSWIRE）——2023年9月5日，RAMM Pharma Corp.（包括其全資子公司，“公司” 或 “RAMM”）（CSE：RAMM）宣佈打算以每單位0.05美元的價格完成公司高達2,000,000套（“單位”）的非經紀私募配售，總收益不超過1,000美元 ,000（“發行”）。每個單位將由公司資本中的一股普通股（每股均爲 “普通股”）和一份普通股購買權證（每份均爲 “認股權證”）組成，每份認股權證的持有人有權在發行截止之日後的36個月內以0.05美元的價格收購一股普通股。本次發行的收益預計將用於營運資金和一般公司用途。本次發行預計將於2023年9月26日左右結束。
Ramm also announced its intention to commence a normal course issuer bid (the "NCIB"), under which it could have purchased up to 5% of the current number of issued and outstanding Common Shares. The NCIB would have commenced on or about September 5, 2023 and expired on the 12-month anniversary of the effective date of the NCIB.
拉姆還宣佈打算開始正常發行人競標（“NCIB”），根據該出價，它本可以購買當前已發行和流通普通股數量的5％。NCIB將在2023年9月5日左右開始，並在NCIB生效之日12個月週年之日到期。
Further reference to the proposed non-brokered private placement and the NCIB can be found on the Company's announcement released on September 5th 2023.
有關擬議的非經紀私募和NCIB的更多參考可以在公司於2023年9月5日發佈的公告中找到。
The Company has received a decision from the CSE dismissing the appeal of its previous decision that the private placement announced by the Company on September 5, 2023 required the approval of the majority of the minority shareholders pursuant to CSE Policy 4.6(2)(iv).
根據CSE政策4.6 (2) (iv)，公司已收到CSE的決定，駁回了對其先前決定的上訴，即公司於2023年9月5日宣佈的私募需要大多數少數股東的批准。
The company will review the decision with counsel.
該公司將與律師一起審查該決定。
About RAMM Pharma Corp.
RAMM Pharma is a leader in the field of cannabinoid pharmacology and product formulation for cannabis- based pharmaceuticals and other hemp-based products with a unique and diversified international production and sales platform. The Company operates an established pharmaceutical and medical product business in Uruguay that has developed several medically registered and approved plant -derived cannabinoid pharmaceutical products that have been authorized for sale and/or compassionate use in several Latin American countries. RAMM also has a pipeline of new products, including registered hemp- based nutrition and specialized veterinary products, in various stages of approval and development, which are produced at the company's state-of-the-art, good-manufacturing-practice-certified formulation facility in Montevideo, Uruguay.
關於 RAMM Pharma Corp.
RAMM Pharma是大麻素藥理學領域的領導者，也是大麻類藥物和其他大麻類產品的產品配方領域的領導者，擁有獨特而多樣化的國際生產和銷售平台。該公司在烏拉圭經營一家成熟的藥品和醫療產品業務，開發了幾種經過醫學註冊和批准的植物衍生大麻素藥品，這些產品已獲准在多個拉丁美洲國家銷售和/或用於同情用途。RAMM還擁有一系列新產品，包括註冊的大麻類營養品和專業獸醫產品，這些產品處於不同的批准和開發階段，這些產品是在該公司位於烏拉圭蒙得維的亞的最先進的、經過良好生產規範認證的配方工廠生產的。
In Europe, RAMM's vertically integrated operations are based in Ragusa, Italy and Elbląg, Poland (60 kilometres east of Gdańsk), and include large extraction and processing facilities. RAMM Pharma includes wholly owned subsidiaries Canapar Corp., HemPoland S.p.a. Z.o.o., Medic Plast SA, Yurelan SA, Glediser SA and RAMM Pharma Holdings Corp.
在歐洲，RAMM的垂直整合業務位於意大利的拉古薩和波蘭的埃爾布拉格（格但斯克以東60公里），包括大型開採和加工設施。RAMM Pharma 包括全資子公司 Canapar Corp.、HemPoland S.p.A. z.o.o.、Medic Plast SA、Yurelan SA、Glediser SA 和 RAMM Pharma Holdings Corp.
Additional information about the Company is available at .
有關該公司的更多信息，請訪問 。
For further information, please contact:
欲了解更多信息，請聯繫：
José Roldan Interim CFO
+598 2513 99 58
info@rammpharma.com
何塞·羅爾丹臨時首席財務官
+598 2513 99 58
info@rammpharma.com
Cautionary Note Regarding Forward-Looking Information
關於前瞻性信息的警示說明
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, the Company's strategies and objectives, and future expansion plans.
本新聞稿包含 “前瞻性信息” 和 “前瞻性陳述”（統稱，”向前 看起來像陳述“) 在適用的加拿大證券立法的含義範圍內。所有陳述，除了 的陳述 歷史的 事實， 是 前瞻的 聲明 和 是 基於 上 期望， 估計 和 預測 截至本新聞發佈之日。任何涉及預測、期望的討論的聲明 信念、計劃、預測、目標、假設、未來事件或表現（經常但不總是使用短語） 例如 “期望” 或 “不期望”，“是 預期”，“預期” 或 “未預期”，“計劃”，“預算”， “預定”、“預測”、“估計”、“相信” 或 “打算” 或此類詞語和短語的變體或說明 某些行動、事件或結果（“可能”、“會”、“可能” 或 “將會” 採取或將要實現）不是 歷史事實陳述，可能是前瞻性陳述。在本新聞稿中，前瞻性聲明 關聯， 其中 其他 事情， 該公司的 戰略 和 目標， 和 未來的擴張 計劃。
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward -looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: future growth potential of the Company; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Uruguayan, Latin American, European and international medical and recreational cannabis markets and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Uruguay or internationally; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward -looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward -looking statements and information contained in this news release. The Company assumes no obligation to update the forward- looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
這些前瞻性陳述基於合理的假設和估計 的管理 發表此類聲明時的公司。展望未來，未來的實際業績可能存在重大差異 陳述涉及已知和未知的風險、不確定性和其他可能導致實際結果的因素， 表演 要麼 成就 的 這 公司 到 物質上 不同 從 任何 將來 結果， 表演 要麼 成就 此類前瞻性陳述所表達或暗示。除其他外，這些因素包括：未來的增長 的潛力 公司；波動 將軍 宏觀經濟狀況；波動 證券 市場； 期望 關於 這 尺寸 的 這 烏拉圭人， 拉丁語 美國人， 歐洲的 和 國際 醫療的 和 娛樂 大麻市場和不斷變化的消費者習慣；公司成功實現業務的能力 目標；擴張計劃；政治和社會不確定性；無法獲得足夠的保險來承保風險 和危害; 以及可能限制種植, 生產, 在烏拉圭或國際上分銷和銷售大麻和大麻相關產品；以及員工關係。 儘管本新聞稿中包含的前瞻性陳述是基於哪些管理層 公司認爲或當時認爲是合理的假設，公司無法向股東保證 實際結果將與此類前瞻性陳述一致，因爲可能還有其他因素導致 結果 不 到 是 如同 預期， 估計的 要麼 預期的。 讀者 應該 不 地方 不適當的 依賴 上 這 向前 -看着 聲明 和 信息 包含了 在 這個 新聞 發佈。 這個 公司 假定 不 義務 到 更新 這 向前- 樣子 聲明 的 信念， 意見， 預測， 要麼 其他 因素， 應該 他們 改變， 除了 如同 規定的 通過 法律。
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
沒有證券交易所、證券委員會或其他監管機構批准或不批准這些信息 包含了 在這裏。
譯文內容由第三人軟體翻譯。